CDK9 and neoplasm: We found 2 cyclin-dependent kinase 9 (CDK9) inhibitors, alvocidib and dinaciclib, acting as potent HB growth inhibitors for the high-risk C2 tumor subtype,5,6 which were then further validated in HB patient-derived xenograft (PDX) models grown in vitro and in vivo.